Fisher & Paykel share price slides hard following FY23 guidance update

The company reaffirmed its posture to the market today.

| More on:
Man going down a red arrow, symbolising a sliding share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fisher & Paykel posted its guidance for the first half of FY23 
  • Investors have sold off shares en masse following the update 
  • In the past 12 months, the Fisher & Paykel share price is down 44% 

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is struggling from the open on Friday following a company update.

At the time of writing, the Fisher & Paykel share price is trading 6% down at $17.98 after it announced its FY23 guidance.

Fisher & Paykel expects slow down in FY23

Detailing its forecasts for the coming 12 months, the healthcare giant said that it anticipates revenue of $670 million and net profit after tax (NPAT) of $85–$95 million.

This signifies an increase in revenue compared to 1H FY20's $570.9 million yet a decline in revenue compared to the prior comparable period, being 1H FY22 at $900 million.

CEO Lewis Gradon said the company had "sold approximately ten years' worth of hardware in two years" creating a high comparison in FY22 as well.

"This does not change the fundamentals of our business or our strategy," he added.

"Our Hospital sales teams are still focused on changing clinical practice and helping ensure the hardware our customers have purchased is used to benefit a broader range of patients requiring respiratory support."

Gross margin for the first half is also expected to land at 60% – 500 basis points below the company's long-term target of 65%.

Part of the contraction in gross profit is due to a shift in sales towards the lower margin consumables segment.

However, despite challenges, it expects that H2 FY23 revenue will be higher than the first half as hospitalisation rates normalize.

"The company is now targeting constant currency operating expense growth of approximately 10%
for the year," it added.

Never before in our history have we changed clinical practice with such a significant advantage.
Our customers already have our hardware, they already have clinical experience with its use, and
they already have access to a huge amount of clinical evidence. This gives us confidence that we
can continue to build on our proven 50-year track record and reach more patients with our
respiratory therapies.

In the past 12 months, the Fisher & Paykel share price is down 44%, and down 41% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

1 ASX stock to consider buying that could be the next ResMed

There are obviously no guarantees in the share market. But if you're willing to take on some risk, the rewards…

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Healthcare Shares

Why this ASX biotech stock could rise a massive 40%

Bell Potter sees big returns on the cards for investors from this speculative stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Is this announcement the real reason for the rise?

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

GLP-1 obesity medicines do the opposite of what ResMed stock investors feared

Internal research from ResMed provides some surprising news for investors on the impact of GLP-1s.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Guess which ASX AI stock rocketed 170% on an AstraZeneca update

Investors are loving this company's announcement on Wednesday.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Guess which ASX All Ords company is being sued by shareholders over stock price losses

Some of this biotech's shareholders aren't happy with management.

Read more »